Morgan Stanley Reiterates Overweight Rating on Abbvie (ABBV) After Pfizer's (PFE) Negative Xeljanz Safety News
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Overweight rating and $116.00 price target on Abbvie (NYSE: ABBV) noting that Rx ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
